A 71-year-old female who was diagnosed with nonobstructive hypertrophic cardiomyopathy since 1999 presented with dyspnea and severe edema on both legs. For the management of her symptom, cardiac surgery including tricuspid annuloplasty, Maze operation and right atrial reduction plasty was performed. During follow-up after cardiac surgery, a plasma \( \alpha \)-galactosidase activity was checked for the screening of Fabry disease and the result was around lower normal limit. DNA analysis was implemented for confirmation and it revealed a heterozygote \( \alpha \)-galactosidase mutation at exon 6 \([c.901C>T (p.Arg301Ter)]\). This case suggests that Fabry disease might be easily undetected, and clinical suspicion is critical.

**KEY WORDS:** Fabry disease · Hypertrophic cardiomyopathy · Tricuspid regurgitation.
performed. Hematoxylin and eosin staining showed a diffuse vacuolization of myocytes and lateralization of nucleus (Fig. 4). Congo-red staining was negative and no definite sarcoid granuloma or amorphous amyloid deposition was identified, which excluded the possibility of cardiac sarcoidosis or amyloidosis. Therefore, initial pathologic diagnosis was vacuolar change of myocyte.

For the management of her symptom, cardiac surgery including tricuspid annuloplasty, Maze operation and right atrial reduction plasty was performed. After surgery, her symptom was improved to mild exertional dyspnea (New York Heart Association functional class I–II) and the edema on both legs decreased. ECG showed normal sinus rhythm. On echocardiography, tricuspid regurgitation was reduced to mild to moderate and a moderate resting pulmonary hypertension was noted with a maximal velocity of tricuspid regurgitation of 3.5 m/sec. During follow-up after cardiac surgery, a plasma α-galactosidase activity was checked for the screening of Fabry disease. The result of plasma α-galactosidase activity was around lower normal limit (30.1 nmol/hr/mg, reference range: 25-126 nmol/hr/mg). DNA analysis was implemented for confirmation and it revealed a heterozygote α-galactosidase mutation at exon 6 [c.901C>T (p.Arg301Ter)] (Fig. 5).

After the diagnosis, her history and physical findings were meticulously reviewed. Since teenager, she had pain on the palms and soles (acroparesthesia), hypohidrosis and a heat and cold intolerance. On physical examination, angiokeratomas were found on her lower abdomen. Ophthalmic examination showed a sign of corneal opacity and severe corneal verticillata (Fig. 6), and conjunctival vascular tortuosity. No retinal vascular tortuosity was found on fundoscopic examination. The pure tone audiometry showed a sensorineuronal hearing loss (Fig. 7). The albumin/creatinine ratio (141.4 mg/day, reference range: 0–100 mg/day) and the amount of 24-hour urine

![Fig. 1. Electrocardiogram shows atrial fibrillation and ST-T change with a mean ventricular rate of 56 bpm.](image1)

![Fig. 2. Transthoracic echocardiography shows a markedly thickened wall of left ventricle with a high echo density (A) and severe tricuspid regurgitation (B).](image2)

![Fig. 3. Cardiac magnetic resonance image shows a fuzzy delayed Gadolinium enhancement at the mid anterolateral and inferolateral myocardium of the left ventricle (arrow).](image3)
protein (7837.0 mg/g, reference range: 0–30 mg/g) were increased.

She started to be treated with enzyme replacement therapy (ERT) using α-galactosidase. On the family screening, her younger sister and her first son were turned out to be affected by Fabry disease. Her younger sister who was 66 years old had renal dysfunction. Her first son who was 44 years old had acroparesthesia on hands and feet and hypohidrosis since he was 9 years old. His proteinuria and abnormal ECG were detected since 2014, and left ventricular hypertrophy was observed on his echocardiographic examination.

**DISCUSSION**

Fabry disease is a X-linked recessive metabolic disorder characterized by deficient activity of the lysosomal hydrolase, α-galactosidase A. This enzymatic defect leads to the progressive accumulation of glycosphingolipids, predominantly globotriaosylceramide (Gb3), within the lysosomes of endothelial cells. The clinical manifestations depend on the part of body which is damaged, and acroparesthesias, hypohidrosis, corneal opacities (cornea verticillata) and dysfunction of the kidney, brain, and heart can be developed.

Cardiac manifestation can be seen in almost all patients, but symptoms from the cardiovascular system appear much later than Gb3 accumulation starts. The mean age of cardiac symptom onset is 32 years and 40 years in male and female patients, respectively. The cardiovascular complications include myocardial hypertrophy of the left ventricle, thickening of the valves, dilatation of the ascending aorta and conduction disturbances. In the end stage of cardiomyopathy caused by Fabry disease, myocardial fibrosis is extensive, and systolic and diastolic left ventricular functions become severely impaired. In our case, a severe ventricular hypertrophy was developed, which might resulted in atrial fibrillation and tricuspid regur-

---

**Fig. 4.** Histology shows a diffuse vacuolization of myocytes (arrow) causing large clear spaces in the myocardial cells and lateralization of nucleus (hematoxylin and eosin, × 200).

**Fig. 5.** Automated sequencing profile of genomic DNA reveals a heterozygote α-galactosidase A mutation at exon 6 [c.901C>T (p.Arg301Ter)].

**Fig. 6.** Slit lamp examination shows corneal opacity and severe corneal verticillata (arrow).
Gitation. Myocardial echo density was very high, resembling the typical feature of myocardial sparkling found in cardiac amyloidosis. However, ECG did not show a low voltage which is typically caused by interstitial infiltration of amyloid, and amyloid infiltration was not found in myocardial biopsy.

Fabry disease cardiomyopathy mimics HCM and infiltrative disease in respect to the morphologic and clinical features. Therefore, differential diagnosis is not easy and frequently relies on invasive studies such as endomyocardial biopsy or molecular and gene analysis. In particular, Fabry disease cardiomyopathy shares many clinical and morphologic features with HCM, and Fabry disease cannot be differentiated if we do not suspect and pay attention to systemic manifestations of this disease. However, some clues of Fabry disease can be found in heart. On echocardiography, patients with HCM show more frequently present with asymmetric septal hypertrophy and outflow tract pressure gradient in comparison with patients with Fabry disease. A binary appearance of left ventricular endocardial border, reflecting the endocardial and subendocardial compartmentalization of glycosphingolipid material, can be a good indicator of Fabry cardiomyopathy. Tissue Doppler imaging, and strain rate imaging can help to detect early diastolic dysfunction due to regional fibrosis in Fabry disease.

Cardiac magnetic resonance has no pathognomonic finding of Fabry disease, but the difference of focal late enhancement pattern can be helpful. In most Fabry disease patients (92%), late gadolinium enhancement was noted in the basal infero-lateral walls. In Fabry cardiomyopathy, endomyocardial biopsy shows cardiomyocytes containing large perinuclear and cytoplasmic vacuoles representing accumulation of glycolipid material and the characteristic appearance of lamellar bodies inclusion in electron microscopy, whereas HCM shows only disarrayed hypertrophied myocytes without cytoplasmic vacuoles.

The diagnosis of Fabry disease starts from clinical suspicion. If there are 2 or more clinical problems among acroparesthesia or neuritic pain in hands or feet, persistent proteinuria of unknown cause, progressive renal impairment of obscure cause, unexplained HCM, angiokeratomas etc., high suspicion of Fabry disease should be raised, then galactosidase A activity assays should be checked for screening. In affected males, enzyme assays usually show severely diminished activity in plasma and leukocytes and Fabry disease diagnosis can be confirmed without further exam. However enzyme activity in heterozygote female is usually normal as in our case, confirmation exam such as detection of a gene mutation or tissue biopsy is needed, if the patient is suspicious of Fabry disease. After a Fabry disease-specific gene mutation is identified or cytoplasmic vacuoles in light microscopy or lamellar bodies inclusion in electron microscopy on biopsy tissue is noted, Fabry disease can be confirmed. All family members suspected of having Fabry disease should be tested, even if they have no symptoms. Patients with unexplained left ventricular hypertrophy should be checked if they have symptoms related to Fabry disease.

ERT with galactosidase is the specific therapy for Fabry disease. ERT stabilizes the levels of Gb3 in the endothelial cells of the myocardium leading to reduce fibrosis development, and consequently improves left ventricular function. How-

![Fig. 7. Audiogram shows bilateral sensorineural hearing loss. Bone conduction loss is noted above 4 kHz.](image-url)
ever, the treatment is effective when the disease’s state is early and myocardial fibrosis is in a low degree.14 Regarding other systems, treatment reduces neuropathic pain, stabilizes renal function and contributes to the regression of the major pathological complications as well as to an improvement in prognosis.

Fabry disease might be easily undetected, and clinical suspicion is critical. Our case was not diagnosed with Fabry disease until cardiac surgery was performed to correct severe tricuspid regurgitation and atrial fibrillation. If Fabry disease was confirmed earlier and ERT was started, ventricular hypertrophy might be regressed before cardiac surgery was required.

References
1. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Wible T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
2. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshiida A, Kuriyama M, Hayashi H, Sakuraba H, Tanaka H. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
3. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110:1047-53.
4. Kampmann C, Baehner F, Whybra C, Martin C, Wierthoff CM, Ries M, Gal A, Beck M. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002;40:1668-74.
5. Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004;144(5 Suppl):S20-6.
6. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetová D, Zeman J, Ledvinoví J, Poupétová H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 2000;139:1101-8.
7. Weidemann F, Breunig F, Beer M, Sandstedt J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26:1221-7.
8. Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, Russo MA, Frustaci A. Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006;47:1663-71.
9. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:1978-84.
10. Toro R, Perez-Isla L, Doozakaquis G, Barba MA, Gallego AR, Pintos G, Barbados FJ, Matgas A, Zamorano JL. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009;132:38-44.
11. Moon JC, Sachdev B, Elkingston AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5.
12. Koitabashi N, Utsugi T, Seki R, Okamoto E, Sando Y, Kaneko Y, Nagai R. Biopsy-proven cardiomyopathy in heterozygous Fabry’s disease. Jpn Circ J 1999;63:572-5.
13. Weidemann F, Breunig F, Beer M, Sandstedt J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301.
14. Koskennuovo JW, Harttala JJ, Nuutila P, Kallikotoski R, Viikari JS, Engblom E, Penttinen M, Knutti J, Mononen I, Kantola IM. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 2008;31:432-41.
15. Eng CM, Guflon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9-16.